Repeated intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents are needed to stabilize vision for patients with neovascular AMD, and it is also important for individuals at risk for progression to more advanced stages of AMD (e.g., patients with early-stage non-neovascular AMD and/or a family history of AMD) to have regular dilated eye examinations to allow for adequate monitoring of disease progression and early detection of intermediate or advanced disease42. This evidence concerns the gene VEGFA and age-related macular degeneration.